कृपया अन्य खोज का प्रयास करें
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was founded in 1984 and is headquartered in Stockholm, Sweden.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Daniel Kaufman | 65 | 1996 | Member of the Scientific Advisory Board |
Mark A. Atkinson | 62 | 1997 | Chairman of Scientific Advisory Board & Independent Director |
Maria-Teresa Essen-Möller | 53 | 2009 | Independent Director |
Anders Essen-Möller | 82 | 1996 | Independent Chairman |
Ake Lernmark | 78 | 1996 | Member of the Scientific Advisory Board |
Torbjörn Bäckström | 75 | 2017 | Independent Director |
Karin M. Hehenberger | 51 | 2021 | Independent Director |
Karin Rosen | 56 | 2023 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है